Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock
Needham said the FDA outcome was better than expected because the regulator could have demanded meaningful changes to Rocket’s Danon disease trial. Needham upgraded Rocket Pharmaceuticals to ‘Buy’ from ‘Hold’ with a $9 price target, according to The Fly. The FDA said that Rocket could continue enrolling and dosing patients in the Phase 2 study … Read more